SEC and FDA sign 3-year market integrity pact
The SEC and FDA signed a three-year cooperation agreement on Aug. 31 that gives the agencies formal channels for exchanging nonpublic information about regulated products, public companies and potential legal violations. SummaryThree-year SEC-FDA agreement creates formal channels for exchanging information about regulated products and public companies.The SEC may use FDA information in filing reviews, investigations, proceedings, and civil enforcement actions.FDA referrals will involve its chief counsel, while two SEC divisions maintain designated contacts internally.Shared nonpublic records remain confidential and generally require written permission before any further external disclosure.Either agency may terminate the agreement with thirty days notice during its three-year operating period. The MOU allows the Securities and Exchange Commission to use information obtained from the Food and Drug Administration during company filing reviews, enforcement investigations, administrative proceedings and civil actions. The agreement takes effect immediately. It does not announce an investigation, new disclosure rule or enforcement case against any company. It instead creates procedures that could help the agencies compare corporate statements with information held by the FDA. The MOU establishes a framework for the agencies to enhance cooperation in their regulatory and enforcement responsibilities in order to improve market oversight and compliance. https://t.co/XUAf4rlo7a — U.S. Securities and Exchange Commission (@SECGov) August 31, 2026 You









